The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients

Reiji Yoshimura, Taro Kishi, Akihito Suzuki, Wakako Umene-Nakano, Atsuko Ikenouchi-Sugita, Hikaru Hori, Koichi Otani, Nakao Iwata, Jun Nakamura

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Background: We investigated the relationship between a brain-derived neurotrophic factor (BDNF) polymorphism (Val66Met) and the clinical response of patients with major depressive disorder to selective serotonin reuptake inhibitors (SSRIs; here, paroxetine and sertraline). In addition, serum BDNF levels in these patients were considered together with the clinical response. Methods: A total of 132 patients who met the DSM-IV criteria for major depressive disorder were enrolled in the study. 54 of these patients were male and 78 were female (age range, 20-74. years; mean ± S.D., 51 ± 15). The patients' clinical improvement was evaluated using the 17-item Hamilton Rating Scale for Depression (HAMD-17) before (T0) and at 8. weeks after the administration of SSRI treatment (T8). Patients with at least a 50% decrease in the HAMD-17 score were classified as responders. Results: No correlation was observed between the BDNF Val66Met polymorphism and response to SSRIs or between the BDNF Val66Met polymorphism and serum BDNF levels at T0. An inverse correlation was found between serum BDNF levels and HAMD-17 scores at T0. Conclusions: These results suggest that the BDNF Val66Met polymorphism is independent of both the response to SSRI treatment and serum BDNF levels. The findings in the present study reconfirm that the serum BDNF level is a state biomarker for depression.

Original languageEnglish
Pages (from-to)1022-1025
Number of pages4
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume35
Issue number4
DOIs
Publication statusPublished - 01-06-2011

Fingerprint

Brain-Derived Neurotrophic Factor
Serotonin Uptake Inhibitors
Serum
Major Depressive Disorder
Depression
Sertraline
Paroxetine
Diagnostic and Statistical Manual of Mental Disorders
Biomarkers
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Biological Psychiatry

Cite this

Yoshimura, Reiji ; Kishi, Taro ; Suzuki, Akihito ; Umene-Nakano, Wakako ; Ikenouchi-Sugita, Atsuko ; Hori, Hikaru ; Otani, Koichi ; Iwata, Nakao ; Nakamura, Jun. / The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients. In: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2011 ; Vol. 35, No. 4. pp. 1022-1025.
@article{ea8fe95512404ea484f6d3915954f5d2,
title = "The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients",
abstract = "Background: We investigated the relationship between a brain-derived neurotrophic factor (BDNF) polymorphism (Val66Met) and the clinical response of patients with major depressive disorder to selective serotonin reuptake inhibitors (SSRIs; here, paroxetine and sertraline). In addition, serum BDNF levels in these patients were considered together with the clinical response. Methods: A total of 132 patients who met the DSM-IV criteria for major depressive disorder were enrolled in the study. 54 of these patients were male and 78 were female (age range, 20-74. years; mean ± S.D., 51 ± 15). The patients' clinical improvement was evaluated using the 17-item Hamilton Rating Scale for Depression (HAMD-17) before (T0) and at 8. weeks after the administration of SSRI treatment (T8). Patients with at least a 50{\%} decrease in the HAMD-17 score were classified as responders. Results: No correlation was observed between the BDNF Val66Met polymorphism and response to SSRIs or between the BDNF Val66Met polymorphism and serum BDNF levels at T0. An inverse correlation was found between serum BDNF levels and HAMD-17 scores at T0. Conclusions: These results suggest that the BDNF Val66Met polymorphism is independent of both the response to SSRI treatment and serum BDNF levels. The findings in the present study reconfirm that the serum BDNF level is a state biomarker for depression.",
author = "Reiji Yoshimura and Taro Kishi and Akihito Suzuki and Wakako Umene-Nakano and Atsuko Ikenouchi-Sugita and Hikaru Hori and Koichi Otani and Nakao Iwata and Jun Nakamura",
year = "2011",
month = "6",
day = "1",
doi = "10.1016/j.pnpbp.2011.02.009",
language = "English",
volume = "35",
pages = "1022--1025",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "4",

}

The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients. / Yoshimura, Reiji; Kishi, Taro; Suzuki, Akihito; Umene-Nakano, Wakako; Ikenouchi-Sugita, Atsuko; Hori, Hikaru; Otani, Koichi; Iwata, Nakao; Nakamura, Jun.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 35, No. 4, 01.06.2011, p. 1022-1025.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients

AU - Yoshimura, Reiji

AU - Kishi, Taro

AU - Suzuki, Akihito

AU - Umene-Nakano, Wakako

AU - Ikenouchi-Sugita, Atsuko

AU - Hori, Hikaru

AU - Otani, Koichi

AU - Iwata, Nakao

AU - Nakamura, Jun

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Background: We investigated the relationship between a brain-derived neurotrophic factor (BDNF) polymorphism (Val66Met) and the clinical response of patients with major depressive disorder to selective serotonin reuptake inhibitors (SSRIs; here, paroxetine and sertraline). In addition, serum BDNF levels in these patients were considered together with the clinical response. Methods: A total of 132 patients who met the DSM-IV criteria for major depressive disorder were enrolled in the study. 54 of these patients were male and 78 were female (age range, 20-74. years; mean ± S.D., 51 ± 15). The patients' clinical improvement was evaluated using the 17-item Hamilton Rating Scale for Depression (HAMD-17) before (T0) and at 8. weeks after the administration of SSRI treatment (T8). Patients with at least a 50% decrease in the HAMD-17 score were classified as responders. Results: No correlation was observed between the BDNF Val66Met polymorphism and response to SSRIs or between the BDNF Val66Met polymorphism and serum BDNF levels at T0. An inverse correlation was found between serum BDNF levels and HAMD-17 scores at T0. Conclusions: These results suggest that the BDNF Val66Met polymorphism is independent of both the response to SSRI treatment and serum BDNF levels. The findings in the present study reconfirm that the serum BDNF level is a state biomarker for depression.

AB - Background: We investigated the relationship between a brain-derived neurotrophic factor (BDNF) polymorphism (Val66Met) and the clinical response of patients with major depressive disorder to selective serotonin reuptake inhibitors (SSRIs; here, paroxetine and sertraline). In addition, serum BDNF levels in these patients were considered together with the clinical response. Methods: A total of 132 patients who met the DSM-IV criteria for major depressive disorder were enrolled in the study. 54 of these patients were male and 78 were female (age range, 20-74. years; mean ± S.D., 51 ± 15). The patients' clinical improvement was evaluated using the 17-item Hamilton Rating Scale for Depression (HAMD-17) before (T0) and at 8. weeks after the administration of SSRI treatment (T8). Patients with at least a 50% decrease in the HAMD-17 score were classified as responders. Results: No correlation was observed between the BDNF Val66Met polymorphism and response to SSRIs or between the BDNF Val66Met polymorphism and serum BDNF levels at T0. An inverse correlation was found between serum BDNF levels and HAMD-17 scores at T0. Conclusions: These results suggest that the BDNF Val66Met polymorphism is independent of both the response to SSRI treatment and serum BDNF levels. The findings in the present study reconfirm that the serum BDNF level is a state biomarker for depression.

UR - http://www.scopus.com/inward/record.url?scp=79956009846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956009846&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2011.02.009

DO - 10.1016/j.pnpbp.2011.02.009

M3 - Article

C2 - 21338649

AN - SCOPUS:79956009846

VL - 35

SP - 1022

EP - 1025

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 4

ER -